All Drug discovery and development articles
View all stories with this category.
-
FeatureOne hundred years of insulin
Mike Sutton looks at the journey the diabetes treatment took from the Toronto miracle to mass-production – via a controversial trip to Stockholm
-
Opinion
Opening up a cellular black box
Working out how biomolecular condensates work may reveal a lot about the success or failure of different drugs
-
News
Race to understand Sars-CoV-2 variants amid fears virus might evade vaccines
Biochemical basis behind coronavirus variants’ success could hold key to defeating them
-
Business
BMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
Feature
Supermetals versus superbugs
With pathogenic bacteria rapidly overcoming our arsenal of organic antibiotics, James Mitchell Crow asks if it is time to revisit metal-based antimicrobials
-
Business
Regeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
Business
Alzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
Business
Morphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
Business
Striving to bolster the antibiotic pipeline before it becomes the next crisis
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D
-
Opinion
The side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
Research
Machine learning tool sets out to find new antimicrobial peptides
IBM researchers say their fully automated AI-driven system could speed up the discovery of molecules for novel antibiotics
-
Business
Antibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
-
Opinion
How the pandemic might change drug research
Derek Lowe muses on some positive lessons learned
-
Business
Coronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
Feature
Drugging RNA
Some medicinal chemists have changed their focus from proteins to target RNA, finds Rachel Brazil
-
Webinar
Physics-based computational modeling applied to the design and optimisation of biologics
Explore how FEP technology (including FEP+) can be applied in protein engineering work
-
Sponsored
AstraZeneca puts academia at the heart of pharma
At the heart of chemical biology are the molecules that make medicines effective and safe for consumers. AstraZeneca harnesses the scientists at the heart of academia to create a healthier world
-
News
Oxford University to open antimicrobial research centre after £100m donation from Ineos
Petrochemical giant highlights dangers of antibiotic resistance
-
Opinion
Ruling out the rule of five
Simple calculations for clinical trial success failed to find a winning formula
-
News
Decoding the virus – what we know about Sars-CoV-2 a year on
Scientists have never learnt so much about a pathogen in such a short time
